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Abstract
At the clinical level comorbidity between chronic pain and dysfunctional hypothalamus-pituitary-adrenal (HPA) axis is well
established. We aimed to identify causal relationships in a model of neuropathic pain (chronic constriction injury, CCI) by
studying the effects of glucocorticoid receptor agonist (dexamethasone) and antagonist (RU-486) administration on pain
behavior and spinal biochemical mediators. Daily injections were performed in Sprague Dawley rats. Weight, plasma
corticosterone levels and mechanical pain thresholds were assessed before and during 21 days post-CCI. At days four and
21 we investigated the mRNA expression of spinal mediators. In the dexamethasone-injected group, we observed a
diminution of body weight and plasma corticosterone levels during the 21 days post surgery period and a more
pronounced pain sensitivity until day 7 post-CCI. This enhanced pain sensitivity in the early period following nerve injury
was accompanied by a transient increase of the glutamate receptors mGluR5 and NMDA at day 4. However, at this time
point we did not observe any effect of the agonist/antagonist injections on the mRNA expression of pro-inflammatory
cytokines. The RU-486-injected rats showed a slight mechanical hypoalgesia until 7 days post-CCI, but without any
significant correlation with the expression of the measured markers. Our results indicate that glucocorticoid-related
modulations of neuropathic pain processing may rather depend on a modification of glutamatergic transmission than on a
change in pro-inflammatory cytokine expression.
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Introduction
Comorbidities between chronic pain states and a dysfunctional
hypothalamus-pituitary-adrenal (HPA) axis have repeatedly been
described [1,2]. In this framework, research has mainly focused on
relationships between adrenocortical reactivity and inflammatory
pain states [3,4]. Recently, experimental studies have used
pharmacological approaches to confirm that altered glucocorticoid
processing may have a causal influence on pain sensitivity [5,6]. A
reduced adrenocortical reactivity (relative hypocortisolism) that
may e.g. be related to chronic exposure to stress may hence lead to
an exacerbation of pain [7].
Under physiological conditions, the activation of the HPA axis
leads to the production of glucocorticoids (GCs), steroid hormones
that bind to two kinds of receptors, the mineralocorticoid receptors
(MR) and the glucocorticoid receptors (GR) [8]. The GCs can act
at the transcriptional level via the translocation of the complex
GC-GR to the nucleus which will in turn lead to an enhancement
or repression of the transcription of specific target genes [9,10].
The GCs are known to have an impact on neuropathic pain,
especially through their GR receptor, which is upregulated after
chronic constriction injury (CCI) [11,12]. Allodynia and hyperal-
gesia were prevented by a treatment with a GR antagonist, RU-
486 while a GR agonist (dexamethasone) administration exacer-
bated the pain sensitivity in CCI rats [11].
In neuropathic pain models, an inflammatory component is
involved, especially in CCI [13,14]. Potential effects of pro-
inflammatory cytokines should hence be taken into account. Due
to the activation of glial cells during central and peripheral
sensitization, a release of pro-inflammatory cytokines having a
major impact on neuronal activation, on glial cell activity and on
the secretion of other factors from these cells has been observed.
TNFa is known to be implicated in the initiation and maintenance
of central sensitization [15] and to enhance neuronal sensitivity to
thermal and mechanical stimulation [16]. Il-1b is well known to
increase calcium conductance to the intracellular milieu through
the NMDA receptor in nociceptive spinal cord neurons [17]. The
GCs have powerful anti-inflammatory effects that could e.g.
reduce the pain response via an inhibition of the release of the
mentioned pro-inflammatory cytokines [18].
Additional biochemical pathways depending on glucocorticoids
and significantly altering nociceptive processing have mainly been
described in neuropathic pain models. The activation of GR can
impact on the glutamatergic system through an upregulation of
NMDA receptors and a downregulation of the excitatory amino-
acid transporter EAAT3 [11,19,20]. In contrast to the inhibition
of cytokine release and concomitant reduction of pain sensitivity,
GR activation may hence also lead to an enhancement of
glutamatergic transmission resulting in exacerbated nociceptive
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processing. In this case, the glucocorticoids play an important
active role in central sensitization, participating in the initiation of
neuropathic pain and facilitating the accumulation of extracellular
glutamate [21]. In a normal configuration, glutamate is removed
from the synaptic cleft by transporters located on neurons
(EAAT3) and on glial cells (EAAT2). Besides the involvement of
the ionotropic NMDA receptor, the metabotropic receptor
mGluR5 has also been demonstrated to be implicated in the
central sensitization induced by a CCI model of neuropathic pain
[22].
The goal of the present pharmacological study was to
investigate the impact of GC on spinal markers of nociceptive
processing in a model of neuropathic pain. To mimic states of
hyper- and hypo-cortisolism, we used daily administrations of GR
agonists (dexamethasone) and antagonists (RU-486) in rats with
chronic constriction injury.
We measured metabolic parameters, such as the weight and the
plasma corticosterone levels, as well as the repercussion of these
treatments on mechanical pain thresholds. Concerning potentially
involved biochemical cascades, we investigated markers of the two
opposite pathways described above. More specifically, we studied
the mRNA expression of the pro-inflammatory cytokines TNFa
and IL-1b, of ionotropic (NMDA, through its subunits NR1 and
NR2a) and metabotropic (mGluR5) glutamate receptors as well as
of the glial and neuronal glutamate transporters EAAT2 and
EAAT3.
Materials and Methods
Animals
Experiments were performed in 50 adult 50–60 days old male
Sprague Dawley rats weighing 207–382 g. Male rats were used to
avoid effects of estrogens on glucocorticoid release. The animals
(Harlan Laboratories, Netherlands) were housed three per cage in
a temperature-controlled room (20–22uC) under a 12 h day-night
cycle. Food and water were provided ad libitum. The body weight
was regularly controlled. Starting two weeks before initiation of the
experiments, the animals were handled daily and habituated to the
behavioral testing room and devices. The Animal Care and Use
Committee of the University of Luxembourg approved all animal
procedures.
CCI surgery
For chronic constriction injury (CCI) surgery, all rats were
anesthetized with isoflurane using an anesthesia unit (Univentor
400, Zejtun, Malta). The right sciatic nerve was exposed and three
natural chromic gut 4–0 (Stoelting Europe, Dublin, Ireland) loose
ligatures were placed around the nerve. The distance between two
ligatures was 1 mm. The muscle layer was closed with 4–0 silk
sutures and the skin layer was closed with surgical skin staples.
Experimental protocol
The rats were divided into three groups receiving daily
injections of either dexamethasone (DEX, n = 16), or RU-486
(RU, n = 17) or vehicle (CON, n = 17) from two days before the
surgery until the end of the experiment. Ten animals per group
were sacrificed already 4 days after the CCI surgery to measure
early changes in the expression level of spinal mediators. The
remaining rats (DEX: n = 6, RU: n = 7, CON: n = 7) underwent a
long term experiment. They were sacrificed at day 21 post surgery
and their spinal cord was also examined for spinal mediator
mRNA.
The course of the experiments was as follows: mechanical pain
thresholds were assessed on three consecutive days (d-5, d-4 and d-
3) to reveal baseline values (BS). The daily pharmacological
treatment started at d-2 and on this day and the two following ones
(d-2, d-1, d0) mechanical thresholds were also measured (baseline
with injections, BSi) to test for drug effects. At d0 CCI surgery was
performed and pain sensitivity measurements were done on
days 4, and for the long term groups additional on days 7, 10, 14,
and 21. Blood sampling was carried out on d-2 (BS), d0 (BSi) and
on days 1, 4, and 7, 14 and 21 following CCI surgery. Animals
were sacrificed after the experiments on day 4 or 21 and the spinal
cord was removed and processed for qPCR. Weight, corticoste-
rone levels and behavioral data of the animals sacrificed at day 4
were in the same range as those measured in the long term group.
For this reason only the data covering the 21 days of experiment
are presented.
Von Frey monofilament test
The Von Frey test was used to measure mechanical allodynia/
hyperalgesia. Rats were placed in PlexiglasH cages with wire mesh
bottoms and given 10 min to acclimate. Each monofilament
(OptiHair, MarstockNervTest, Germany) was placed perpendic-
ularly onto the midplantar region of the hind paw and pressure
was increased until the point of deflection of the filament was
reached. Pain thresholds were determined by the ascending and
descending method of limits with forces ranging from 8 to 256 mN
in 11 logarithmic steps [23]. Each test was repeated three times
and the mean was calculated for each paw.
We set the values of the left unaffected side (control) to 100%
and expressed the threshold of the right injured paw as a
percentage of the left one.
Blood sampling and measurement of corticosterone
levels
Blood sampling was performed in awake animals between 9 h
and 9 h30, half an hour before the injections. To minimize stress
reactions, rats were loosely held in a towel and then a small
incision at about 15 mm from the end of the tail was performed
using a scalpel. 300 ml of blood was collected with a capillary tube
coated with EDTA (Microvette CB300, Sarstedt, Essen, Belgium).
The samples were immediately placed on ice, then centrifuged for
10 min at 4uC and the plasma was removed and stored at 220uC.
Serum corticosterone levels were measured using an ELISA
(Enzyme-Linked Immunosorbent Assay) kit (Assay Designs, USA).
Analysis was done according to the manufacturer’s protocol. Data
were acquired via a plate reader (Sunrise Magellan, Austria) using
an adequate software package (Magellan software, v6.4 standard,
Austria).
Injections of dexamethasone, RU-486, or vehicle
The first day of injection (d-2) preceded the surgery by two days
and the injections were repeated daily until the end of
experimentation at d4 or d21. The groups received daily
intraperitoneal injections of either dexamethasone, a GR agonist
(dexamethasone 21-phosphate disodium salt, Sigma Aldrich,
Germany), at a dose of 0.5 mg/kg/d dissolved in sterile saline
0.9%, or RU-486, a GR antagonist (mifepristone, Sigma Aldrich,
Germany), at a dose of 4 mg/kg/d liquefied in olive oil containing
1% ethanol. The control group was treated either with olive oil
containing 1% ethanol (8 animals) or saline 0.9% (9 animals).
Since these two control groups did not differ in their results, we
pooled the data. The daily injected volume was 0.2 ml. Injections
were always performed at the same hour (10 am), 30 min before
starting the behavioral tests.
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Sample and RNA collection
At day 4 or 21 post surgery, rats were deeply anesthetized with
isoflurane and decapitated. Levels L4/L5 of the spinal cord were
removed and the total RNA was extracted with the Invitrap Spin
Tissue RNA Microkit (Invitek, Germany). The RNA concentra-
tion was determined by measuring the absorbance at 260 nm,
using a Nanodrop ND-2000 spectrophotometer (Thermo Fisher
Scientific, Wilmington, U.S.A.).
Reverse transcription and Real-Time qPCR
Total RNA (500 ng) was reverse transcribed into cDNA using
the ImProm-II Reverse Transcription System (Promega Corpo-
ration, Madison, USA). Real-Time PCR reactions were per-
formed from 10 ng of cDNA with a CFX-96 thermocycler (Bio-
Rad Laboratories, Nazareth, Belgium) using SYBR green Super-
mix PerfeCTa (95053–02K, Quanta Biosciences, Gaithersburg,
MD, USA) and primers for the reference gene, b-actin, and the
genes of interest presented in Table 1.
The steps consisted of one cycle of 3 min at 95uC and 40 cycles
of amplification (10 sec at 95uC, 30 sec at 61uC). All samples were
run in triplicate. Relative expression was estimated using the
DDCt- method [24] with b-actin as the reference. Threshold cycle
values (CT) were used to compute the amount of target gene
mRNA in relation to the reference gene mRNA (b-actin). DCT
represents the difference between the number of cycles that were
necessary to detect the PCR products of the target and the
reference genes. The DDCT indicates the difference between the
DCT of the pharmacologically treated groups and the DCT of the
vehicle treated (CON) animals. The data were expressed as
22DDCT and the mean of the right injured as well as of the left not
affected side was computed for each group. Since we did not
notice any significant differences in the relative expression levels,
we only present the data for the right affected side of the spinal
cord.
Statistical analysis
Statistical analyses for mechanical thresholds and qPCR were
carried out using an analysis of variance (ANOVA) followed by a
Scheffe´ post hoc test to identify differences between groups.
Regarding the weight and corticosterone levels a Dunnett T3 post
hoc test was used. P,0.05 was defined as the level of statistical
significance. Statistical tests were performed with IBM SPSS
Statistics version 19 (IBM corporation, Somers, NY, USA).
Results
Effect of GR-antagonist/agonist administration and CCI
surgery on metabolism
The weight of the rats was followed up from 7 days before to
21 days post-CCI at different time intervals (Fig. 1). At the start of
the experiment, at d-7, the mean weight was identical in all three
groups (DEX: 289.83618.25 g, RU: 297.33620.18 g, CON:
291618.15 g). A normal increase in weight was then observed at
d-5 (DEX: 309.75614.60 g, RU: 319.17616.20 g, CON:
313.17614.24 g).
With the start of the drug injections the animal weight in the
DEX group decreased constantly, regardless of the CCI surgery,
until the end of the experiment at d21 (248.27610.33 g). In
contrast, the rats in the RU group gained weight until d21
(355.75611.05 g) in a time course comparable to the one seen for
CON (d21: 361.83610.03 g). In the two latter groups the nerve
constriction on d0 only slightly slowed down the increase in
weight.
Statistical analysis revealed a significant difference between the
mean weight of DEX animals and CON from d4 (p,0.05) to d21
(p,0.001) and between DEX and RU rats from d7 (p,0.01) until
the end of the experiment at d21 (p,0.001).
Table 1. Sequences of primers used in this study.
Name Accession Sequence
b-actin NM_031144 59 GCT GAG AGG GAA ATC GTG CGT GAC 39
59 GGA GGA AGA GGA TGC GGC AGT GG 39
EAAT2 NM_017215 59 ATG CTC CTC ATT CTC ACA G 39
NM_001035233 59 CTA CAT TGA CCG AAG TTC TC 39
EAAT3 NM_013032.3 59 TCA TAG TCG GGA AGA AC 39
59 AGC GGA ATG TAA CTG GAA GG 39
IL-1b NM_031512 59 GTT GAA TCT ATA CCT GTC CTG TG 39
59 TGG TCT TGA CTT CTA TCT TGT TG 39
TNFa NM_012675 59 GCT CTT CTG TCT ACT GAA CTT C 39
59 GAT CTG AGT GTG AGG GTC TG 39
mGluR5 NM_017012.1 59 ACA ACC TCT ACA GTG GTA CG 39
59 GGC CCA AGT CAC AGA TTT TC 39
NR1 NM_001270607 59 GGT TGC GTG GGC AAC ACC AA 39
59 CCG TCC GCA TAC TTA GAA GA 39
NR2a NM_012573.3 59 CAG ATA ACA ATA AGA ACC ACA AG 39
59 AAC ATC GCT ACA GTC CTT 39
doi:10.1371/journal.pone.0091393.t001
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Alterations of plasma corticosterone concentrations in
response to GR-antagonist/agonist injections and CCI
surgery
The three groups of rats displayed comparable plasma
corticosterone levels at d-5 before the administration of the GR-
agonist or -antagonist (DEX: 219641 ng/ml, RU: 209628 ng/
ml, CON: 173621 ng/ml) (Fig. 2).
Injections of vehicle (CON group) did not alter the blood
corticosterone levels per se (d-1: 159622 ng/ml). The nerve injury
on d0 however resulted in an increase of the corticosterone
concentration from d1 (205629 ng/ml) to the end of the
experiment (d21: 273655 ng/ml). In the DEX group the
concentration of circulating corticosterone decreased following
the administration of dexamethasone and persisted at this low level
throughout the course of the experiment despite the CCI surgery.
Compared to the CON animals the DEX group exhibited
significantly lower corticosterone levels at d1 (p,0.05) and d14
(p,0.01) but not at d7 and d21.
In contrast, injections of the GR-antagonist RU-486 did not
lead to alterations in blood corticosterone levels in the pre-surgery
period (d-1: 216619 ng/ml). However, the nerve constriction on
d0 led to an increase in the concentration of circulating
corticosterone measured on d1 (302636 ng/ml). Throughout
the course of neuropathy the levels remained enhanced. In
comparison with the control group no significant differences were
seen.
Comparing the DEX and RU groups statistically significant
differences were observed at all time points after CCI surgery
except at d14 (d1: p,0.01; d4: p,0.01; d7: p,0.05; d14:
p = 0.129; d21: p,0.05), confirming a strong effect of dexameth-
asone on the plasma corticosterone levels.
Effect of systemic GR-antagonist/agonist treatment on
nerve injury-related mechanical allodynia/hyperalgesia
On the three consecutive days (d-5 to d-3) preceding any
manipulation, rats were tested for baseline mechanical paw
withdrawal (BS). The pain thresholds were expressed in percent-
ages of the right injured paw compared to the left paw that served
as control (Fig. 3). As expected, no difference between the three
groups could be observed (DEX: 98.564.92%, RU:
102.563.79%, CON: 100.761.66%). Thereafter, animals were
injected daily and pain thresholds were again assessed during the
three following days (d-2 to d0) to obtain a baseline under
conditions of drug application (BSi = baseline with injections). We
did not observe any significant differences between the groups
neither under BSi conditions (DEX: 102.662.57%, RU:
10061.26%, CON: 99.364.24%), nor under BS control condi-
tions.
Four days after CCI we noticed, as expected, a pronounced
nerve injury-related increase in pain sensitivity for all three groups.
However, the degree of increase differed between groups. Whereas
the RU animals appeared less sensitive (48.4612.59%) to noxious
mechanical stimulation than CON (31.766.43%), the DEX rats
exhibited a higher pain sensitivity (12.462.04%). This differential
pain sensitivity of the groups was still seen 7 days after surgery
(RU: 52.2069.80%, CON: 29.463.58%, DEX: 13.262.64%). At
d10 and 14, the pain thresholds of RU (16.461.95%) and CON
(1561.13%) further decreased, reaching the same level as DEX
(11.360.46%). Only at d21, the mechanical pain sensitivity
slightly decreased in all three groups (DEX: 39.569.54%, RU:
40.865.83%, CON: 22.561.75%).
Intergroup comparisons revealed that rats receiving systemic
RU 486 treatment were less sensitive to noxious mechanical
stimulation for up to 7 days after CCI surgery than rats with
dexamethasone administration (d4: p,0.05; d7: p,0.01).
Figure 1. Animal weight changes following GR-agonist/antag-
onist treatment and CCI. Influence of daily injections of the GR
agonist dexamethasone (DEX), the GR antagonist RU-486 (RU), or
vehicle (CON) in combination with chronic constriction injury (CCI) on
the rat weight. Administration of the GR agonist resulted in a constant
loss of weight, unaffected by CCI surgery. GR antagonist or vehicle
treated animals exhibited a normal gain of weight, only slightly slowed
down by the CCI surgery. Data are shown as mean 6 s.e.m. **p,0.01,
***p,0.001 indicate significant differences between DEX and RU and
#p,0.05, ##p,0.01, ###p,0.001 represent significant differences
between DEX and CON.
doi:10.1371/journal.pone.0091393.g001
Figure 2. Changes in blood corticosterone concentration
throughout drug administration and CCI periods. Despite CCI
surgery, daily administration of the GR agonist dexamethasone (DEX)
led to a slight decrease of plasma corticosterone levels, persisting
throughout the experiment. Injections of the GR antagonist RU-486 (RU)
or vehicle (CON) per se had no effect on the concentration of circulating
corticosterone. The chronic constriction injury (CCI) however triggered a
persistent increase in plasma corticosterone levels. Data are presented
as mean 6 s.e.m. *p,0.05, **p,0.01 indicate significant differences
between DEX and RU and #p,0.05, ##p,0.01 between DEX and CON.
doi:10.1371/journal.pone.0091393.g002
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Alteration of cytokine expression following
dexamethasone or RU-486 treatment
IL-1b and TNFa are cytokines known to be implicated in
neuropathic pain mechanisms. Four days after surgery the IL-1b
mRNA expression did not display any difference in the three
groups (DEX: 1.3660.21, RU: 1.1760.14 and CON: 1.3260.35)
(Fig. 4A). At d21 post-CCI the expression of this cytokine was
reduced in the DEX group (0.4160.06) but not significantly
changed in rats treated with RU-486 (0.7960.11) in comparison
with the control group (1.0060.13). Statistical analysis revealed a
significant difference at day 21 between DEX and CON (p,0.01)
and also between DEX and RU (p,0.05).
We could observe the same temporal regulation profile for
TNFa. At d4, no significant up- or downregulation of the mRNA
expression of this cytokine was observed in the treated groups
(DEX: 0.8360.10, RU: 1.5360.19 and CON: 1.0560.11).
21 days post surgery the mRNA expression was downregulated
in the DEX group (0.5460.07) but not in the RU rats (0.8760.15)
(Fig. 4B). At this time point we observed a significant difference
between the DEX group and CON (p,0.05).
These data confirm a (late) regulatory effect of dexamethasone
but not of RU-486 on the mRNA expression of the two studied
pro-inflammatory cytokines.
Impact of GR-agonist/antagonist administration on
components of the glutamatergic system
Expression of excitatory amino-acid
transporters. Excitatory amino-acid transporters (EAATs) also
known as glutamate transporters are essential to homeostasis,
permitting the uptake of the neurotransmitter from the synaptic
cleft to regulate its effects. In the present study, we focused on two
of the five subtypes, one, which is located in the membrane of glial
cells (EAAT2) and the other which can be found in the membrane
of neurons (EAAT3, also known as EAAC1).
The mRNA expression of the glial transporter EAAT2 showed
no significant change in the RU group four days (1.9460.10) and
21 days (0.7960.11) after surgery (Fig. 5A). Likewise, the
administration of the GR-agonist had no statistic effect on the
expression of EAAT2, neither under short term (1.4560.3) nor
under long term (1.0060.12) neuropathic conditions.
Regarding the neuronal transporter EAAT3, no significant
alteration in the mRNA expression was found in the DEX group
in the early period (1.7660.29) as well as three weeks following
nerve constriction (0.9360.15). Systemic treatment with RU-486
induced a significant increase in the expression of EAAT3 after
four days (2.5360.22; p,0.01 compared to CON) and came back
to control levels at 21 days (0.9660.11) (Fig. 5B).
Figure 3. Influence of GR-agonist/antagonist treatment and
CCI on mechanical pain thresholds. Treatment of the animals with
either GR agonist dexamethasone (DEX), GR antagonist RU-486 (RU), or
vehicle (CON) did not change the mechanical sensitivity per se. Chronic
constriction injury (CCI) resulted in an increase of pain sensitivity in all
three groups. Dexamethasone receiving rats were more sensitive to
mechanical stimulation than RU-486 injected rats up to seven days post
surgery. Data of the right affected paw are presented as percentage of
the left control paw (mean 6 s.e.m.). Asterisks indicate a significant
difference between the DEX and RU group for the individual time point
(* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0091393.g003
Figure 4. Spinal cytokine mRNA expression following CCI in
dexamethasone and RU-486 treated rats. The relative mRNA
expression levels of (A) IL-1b and (B) TNFa in the right spinal cord
segment L4/L5 were measured at days four and 21 after CCI surgery in
three groups of rats receiving either daily dexamethasone (DEX), RU-
486 (RU), or vehicle (CON) injections. Early after injury activation or
inhibition of GR did not alter the relative expression levels of both
cytokines. In the later phase, the mRNA of IL-1b was downregulated by
dexamethasone and RU-486 treatment, whereas TNFa mRNA levels
were reduced only by GR activation. Data are expressed as mean 6
s.e.m. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0091393.g004
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Taken together, the systemic administration of the GR-
antagonist resulted in a significant increase in mRNA levels of
merely the neuronal glutamate transporter EAAT3. In contrast,
dexamethasone displayed no significant influence on the regula-
tion of the excitatory amino-acid transporters, neither in the early
development nor in later phases of neuropathy.
Expression of glutamate receptors. The metabotropic
glutamate receptor mGluR5 as well as the ionotropic NMDA
receptor are claimed to be involved in neuropathic pain
syndromes. For the latter, seven subunits have been described.
Here, we focused on the two commonly expressed NR1 and NR2a
subunits.
Regarding the mRNA expression of the metabotropic receptor
mGluR5, a transient and significant increase was only seen early
after nerve injury in the DEX (2.8860.14; p,0.001) as well as the
RU group (2.3760.12; p,0.001) as compared to CON
(1.1860.25). At d21 the mRNA expression of mGluR5 came
back to control levels in both treatment groups (DEX: 1.1760.09;
RU: 1.0260.10; CON: 1.0960.21) (Fig. 6A).
For the NR1 mRNA expression, a significant increase was
noticed in the DEX group at d4 (1.7360.16) compared to CON
(1.0060.16; p,0.05). The level returned to baseline at d21 post
surgery (DEX: 1.1760.09, CON: 1.0660.15) (Fig. 6B). Admin-
istration of the GR-antagonist RU-486 had no significant
influence on the NR1 regulation at d4 (1.4460.09) and d21
(1.0260.10).
Neither activation nor inhibition of the GR led to any
significant modification of the NR2a mRNA expression early
after nerve constriction (RU: 1.6160.07; DEX: 1.3260.19; CON:
1.1560.19) (Fig. 6C). However, in the later phase of neuropathy,
the RU group displayed a significant decrease of the relative
expression level (0.5860.0; p,0.05) whereas the level measured in
the DEX group (0.7860.06) was not statistically different from
control (1.0860.19).
Summarizing the effects of pharmacological GR-manipulation
on the expression of glutamate receptors, we observed an early
GR-activation mediated upregulation of metabotropic and iono-
tropic receptors and a late downregulation of one subunit of the
NMDA receptor related to GR-antagonist application.
Discussion
In the present work, we aimed to determine the role of GCs in
the onset and maintenance of mechanical allodynia/hyperalgesia
in a CCI model of neuropathic pain. Our observations included:
1. A decrease in body weight for the DEX group throughout the
21 days following CCI surgery; 2. A higher sensitivity to painful
mechanical stimulation of the DEX group until day 7 post
surgery; 3. A lack of effects of dexamethasone or RU-486
injections on early pro-inflammatory cytokine mRNA expression;
4. No significant differences in EAAT2 mRNA expression at
days 4 and 21 after the CCI surgery but a RU-486-related
increase at day 4 for EAAT3; 5. A pronounced transient increase
in NMDA receptor subunit NR1 and in mGluR5 mRNA
expression in the DEX group at 4 days post surgery; 6. A
decrease in the NMDA receptor subunit NR2a mRNA expression
only 21 days post CCI in the RU group.
Metabolic effects of GR-agonist or -antagonist
administration
In the DEX group consistent decrease in body weight was
observed from the starting day of the injections until the end of the
experiment. Since glucocorticoids are known to imply the
mobilization of fatty acids [8], our findings may be related to
dexamethasone mimicking the effects of endogenous GCs and
provoking a utilization of the mentioned fatty acids and the
concomitant loss of weight. In the present study, plasma
corticosterone levels reflecting HPA axis activity under physiolog-
ical conditions have been modified by the dexamethasone or RU-
486 injections. In the first days of the observation, i.e. in the
absence of any manipulation, no differences were observed
between the three groups. After starting the drug injections, the
plasma corticosterone levels of the DEX group decreased and then
stayed at a stable level from day one to the end of the experiment.
This is consistent with the fact that dexamethasone mimics
endogenous GC effects leading to an activation of the negative
Figure 5. CCI-mediated mRNA expression of spinal EAATs
under GR-agonist/antagonist treatment. The relative mRNA
expression levels of (A) the glial glutamate transporter EAAT2 and (B)
the neuronal glutamate transporter EAAT3 were measured in the right
spinal cord segment L4/L5 at days four and 21 after CCI surgery in three
groups of rats receiving daily injections of either GR agonist
dexamethasone (DEX), GR antagonist RU-486 (RU), or vehicle (CON).
Neither activation nor inhibition of GR significantly influenced the
relative expression levels of EAAT2 at both time points (A). EAAT3
mRNA was upregulated in the acute phase of neuropathy by RU-486
administration but not by dexamethasone. At later stages, modulation
of GR activity did not result in any effect on EAAT3 transcription (B).
Data are expressed as mean6s.e.m.
doi:10.1371/journal.pone.0091393.g005
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feedback control of the HPA axis. For the other two groups, the
increase observed at day one was probably mainly due to the
surgery performed at day zero. At this time point, the dexameth-
asone administration probably masked these surgery-related
variations in the DEX group via the described activation of the
negative feedback loop. The corticosterone concentration in the
RU and CON groups stayed at a higher and relatively constant
level throughout the experiment. This is consistent with data from
Soro and colleagues [25] who failed to observe an effect of RU-
486 on the corticosterone level of Sprague Dawley rats.
Development and maintenance of mechanical allodynia/
hyperalgesia
The measurement of mechanical allodynia/hyperalgesia during
three days without interventions and the three days with drug
injections did not reveal any differences between the groups. In the
absence of any injury, the administration of GR agonists or
antagonists did hence not have any effect on the mechanical pain
thresholds. However, 4 to 7 days after the CCI surgery, the RU
group was significantly less sensitive than the DEX group. This
observation is in accordance with a recent study of Ou and
colleagues [26] highlighting a protective effect of another GR
antagonist, M8046, in CCI-induced neuropathic pain. The pain
thresholds of the CON rats were located between those of the
pharmacologically treated groups during the same period. Our
observations are consistent with studies showing that intrathecal
injections of dexamethasone increase pain-like behaviors in a
spared nerve injury (SNI) model [19] and CCI model of
neuropathic pain and that GR antagonists like RU-486 attenuate
them [20]. These effects are opposite to the well-known anti-
inflammatory and hypoalgesic effects of GR activation and may
suggest that other pathways involving the glutamatergic system
known to have a role in neuropathic pain (for review see [27])
should be more implied in the onset of mechanical allodynia than
the local inflammation. No significant differences in pain
sensitivity between the groups were detected in the later period
following CCI surgery. This could be due to adaptive biochemical
processes and to the implication of other mediators coming into
play following pronounced ongoing pharmacological activation or
inactivation of GRs. It should be noted here that effects related to
pharmacological manipulation of the HPA axis have been
described to display complex and even paradoxical patterns,
depending on factors like dose, site and mode of application and
on duration of the treatment [28]. In this context, Kingery and co-
workers [29] have e.g. observed that once-daily injections of
methylprednisolone had no antihyperalgesic effect in a rat sciatic
nerve transection model while continuous infusion reversed heat
and mechanical hyperalgesia. More specifically turning to
glucocorticoid receptor antagonists, Takasaki and colleagues [12]
described that intrathecal and intraperitoneal injections of RU-
486 produced antinociceptive effects in a mouse model of
neuropathic pain while intracerebroventricular injections had no
effect. The authors however only provided short term observa-
tions. We are not aware of any data on long term effects in this
context. The measurement of the mRNA expression of the
mentioned cytokines as well as glutamate transporters and
transmitters at d21 was partly aimed at considering the time
dependent involvement of implied mediators.
Taken together, our behavioral results seem to emphasize a
more important role of GR modulation in the onset of mechanical
allodynia/hyperalgesia rather than in the longer term mainte-
nance.
Involvement of pro-inflammatory cytokines
As mentioned in the final paragraph of the methods section,
we did not observe significant side differences in the expression
levels of cytokine mRNAs. The same was true for the other
Figure 6. mRNA expression of spinal ionotropic and metabo-
tropic glutamate receptors following GR-agonist/antagonist
administration and CCI. The relative mRNA expression levels of (A)
the metabotropic receptor mGluR5, (B) the subunit NR1 and (C) the
subunit NR2a of the ionotropic NMDA receptor were measured in the
right spinal cord segment L4/L5 at days four and 21 after CCI surgery in
three groups of rats receiving daily injections of either dexamethasone
(DEX), RU-486 (RU), or vehicle (CON). Early after CCI the mGluR5 mRNA
was significantly upregulated by GR activation and inhibition, whereas
the NR1 subunit was significantly upregulated only in the DEX group.
For both receptors no change from control was seen in the late phase
of neuropathy. On the other hand, the NR2a mRNA was not altered in
acute conditions but downregulated at 21 days in the RU group treated
with the GR antagonist. Data are expressed as mean 6 s.e.m. *p,0.05.
doi:10.1371/journal.pone.0091393.g006
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examined biochemical markers. This at first astonishing finding is
reminiscent of the implication of spinal glia and pro-inflamma-
tory cytokines in mirror-image neuropathic pain [30]. Bilateral
labelling of activated microglia in the spinal cord dorsal horn
following a unilateral spared nerve injury has e.g. been described
in rats [31]. The fact that we did not observe altered pain
behavior induced by stimulation of the contralateral (control)
paw in spite of the quite symmetrical biochemical expression of
mRNA levels may be related to a time dependent dissociation
between pain behavior and the measured biochemical parame-
ters. In this sense, Huiging Li and colleagues [32], using a spared
nerve injury model in rats, have e.g. observed elevated pro-
inflammatory cytokine levels with effects of steroid treatment
gradually becoming less apparent while the effects of the same
drug on mechanical sensitivity remained evident on day 7 post
surgery. In our hands, there may also have been a more
pronounced ipsilateral expression of spinal mediators in the
initial phase preceding day 4 after CCI which gradually decayed
and converged with the respective values of the untreated side.
Pro-inflammatory cytokines such as IL-1b and TNFa play an
important role in inflammatory reactions and may also be involved
in neuropathic pain [9,33] and in the initiation and maintenance
of central sensitization [34].
We only observed a pronounced decrease in IL-1b mRNA
expression at day 21 post CCI surgery for the DEX group, as
compared to the two other groups. This is consistent with studies
from cell cultures exhibiting an important diminution in IL-1b
mRNA expression after corticosteroid administration [9,35].
Surprisingly, we did not observe any DEX-related effects on the
mRNA expression of this cytokine at day 4. This negative finding
could reflect that IL-1b may not be involved in the onset of
mechanical allodynia following CCI. We did not have the
possibility to include measurements of protein levels in the present
study. These data could be important for the consideration of
potential posttranscriptional regulation-related effects which may
play a critical role in the regulation of pro-inflammatory cytokine
expression by mitogen activated protein kinase signal transduction
pathways as well as by anti-inflammatory agents and mediators
(for review see [36]). These may in turn depend on a host of factors
that have recently been discussed in detail by Ji and colleagues
[37]. The absence of dexamethasone effects at day 4 post CCI is
however in line with the enhanced sensitivity to mechanical
allodynia/hyperalgesia that may be linked to pro-inflammatory
cytokine-mediated effects.
The TNFa mRNA expression was likewise downregulated in
the DEX group at day 21. This is also in line with other studies
showing a decrease of TNFa expression after administration of
dexamethasone [38,39] and an inhibition of TNFa translation by
GCs [40]. The absence of a significant decrease after 4 days is
coherent with delayed modifications regarding this pro-inflamma-
tory cytokine. In agreement with our results, an inhibition of spinal
TNFa receptor expression following administration of the
synthetic GC methylprednisolone has also been shown, an effect
that may be reversed by the administration of RU-486 [41].
Taken together, our results are in accordance with the anti-
inflammatory effects of GR activation in a later phase. TNFa and
IL-1b are known to activate glia cells [42]. Effects of GR activation
or inactivation on this type of cells thus remain to be considered in
the present context. On the other hand, the fact that the DEX
group was more sensitive to mechanical allodynia/hyperalgesia in
the early phase after surgery may point to the dominance of GR-
mediated enhancement of glutamatergic processing as will be
discussed below.
Role of glutamate transporters
Dexamethasone has been shown to have an inhibitory effect on
the downregulation of glutamate transporters such as EAAT1
( = GLAST), EAAT2 ( = GLT1) and EAAT3 ( = EAAC1) after
chronic morphine administration [43]. Along this line Kalariti and
colleagues [44] have demonstrated an increase in EAAT1 protein
but not mRNA expression in vitro following dexamethasone
administration. GR-activation has also been reported to diminish
EAAT3 expression under conditions of nerve injury, effects
reversed by administration of RU 486 [19]. The decreased
glutamate transporter expression leads to an increase of extracel-
lular glutamate resulting in amplified synaptic transmission
[11,19,20].
In the present study we did not observe any significant change
of EAAT3 mRNA expression in the dexamethasone treated group
at day 4, whereas, at the same time point, the RU group exhibited
an important increase. The EAAT2 mRNA expression was not
affected, neither by dexamethasone nor by RU-486.
Although pointing towards the same direction, these results are
not fully consistent with the studies mentioned above. These
discrepancies may be related to the different models used to induce
neuropathic pain as well as to the doses of the respective drugs that
have been administered. The RU-486 injection-related increase is
however in accordance with the literature. It may participate in
the enhancement of glutamate uptake from the synaptic cleft
leading to a reduction of glutamatergic transmission and of pain
sensitivity as observed in the RU group at days 4 and 7.
Impact on glutamate receptors
Glutamate receptors have also been shown to be involved in
GC-mediated effects in a context of neuropathic pain. In this
framework, the role of the metabotropic receptor mGluR5 has
been investigated under conditions of GR agonist and antagonist
treatment. Kalariti and colleagues [44] demonstrated in vitro that
dexamethasone administration increased mGluR5 mRNA and
protein expression. This result is consistent with our observation at
day 4, where a large increase of mGluR5 mRNA expression was
seen in the DEX group. However, these differences had vanished
at day 21, when the groups also displayed similar mechanical pain
thresholds. These findings seem to support the assumption that
mGluR5 could be more implicated in the onset rather than in the
maintenance of the hypersensitivity observed in the DEX group.
Glucocorticoid-mediated effects on NMDA receptor regulation
have also been studied quite extensively. It has e.g. been shown
that GR activation leads to an upregulation of the NMDA
receptor expression in the hippocampus and that enhanced GCs
levels lead to an increase in glutamatergic transmission [21]. In
addition, after a peripheral nerve injury, a time-dependent and
region-specific upregulation of two subunits of the NMDA
receptor has been observed [11]. More precisely, NR1 and NR2
mRNA expression have been shown to be increased in the
ipsilateral spinal dorsal horn in a CCI model. Furthermore, these
subunit expressions decrease under conditions of RU-486 admin-
istration. These data are in agreement with our results showing a
dexamethasone-related enhancement of mRNA expression of
NR1 four days after surgery in the ipsilateral spinal cord. This
increased expression is accompanied by pain hypersensitivity
exhibited by the DEX group rats at this early time point.
Moreover, we can confirm an antagonist-related downregulation
of the NR2 subunit in later phases of experimentally induced CCI.
In our hands the NMDA receptor subunit NR1 played a role in
the onset rather than in the maintenance of mechanical allodynia/
hyperalgesia whereas the NR2a subunit could subsequently have
taken over a more dominant role.
GCs Enhance Rather than Inhibit Neuropathic Pain
PLOS ONE | www.plosone.org 8 March 2014 | Volume 9 | Issue 3 | e91393
Limitations of the study
A limitation of the study is that we only present mRNA
expression data for the spinal mediators. Regulations on a post-
transcriptional level, e.g. via micro-RNAs could play an important
role. Therefore, measurement of protein expression via western
blotting should be included in further experiments. It should
however be noted that the reliability of this kind of protein
quantification (by using house keeping genes) is currently also
under debate.
Conclusion
The present study demonstrated that at an early time point
post-CCI, the activation of GR leads to an enhancement of
mRNA expression of glutamate receptors accompanied by an
increase in mechanical pain sensitivity.
Under these conditions, GR activation may hence lead to an
intensification of glutamatergic transmission that may outweigh
putative anti-inflammatory effects. Further investigations aimed at
confirming this assumption and at elucidating the underlying
mechanisms will have to include the assessment of protein levels.
The involvement of altered descending pain control pathways will
also have to be considered.
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